Quest Diagnostics Inc
DGX
Company Profile
Business description
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
Contact
500 Plaza Drive
SecaucusNJ07094
USAT: +1 973 520-2700
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
56,000
Stocks News & Analysis
stocks
Ask the analyst: Are markets missing something with CSL?
I catch up with Shane Ponraj after an eventful reporting season for healthcare major CSL.
stocks
This ASX stock’s bubble has well and truly burst
Pandemic related tailwinds are a distant memory for Reece, which looks set to face more competition in Australia.
stocks
Tesla’s stock is in trouble, but this fund manager sees a comeback in 2026
Tesla’s challenges echo past issues the company has overcome, says Zevenbergen’s Joe Dennison.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,215.30 | 13.20 | -0.14% |
| CAC 40 | 7,709.81 | 133.23 | -1.70% |
| DAX 40 | 24,152.87 | 120.25 | -0.50% |
| Dow JONES (US) | 45,418.07 | 135.60 | 0.30% |
| FTSE 100 | 9,265.80 | 55.60 | -0.60% |
| HKSE | 25,541.43 | 16.51 | 0.06% |
| NASDAQ | 21,544.27 | 94.98 | 0.44% |
| Nikkei 225 | 42,501.93 | 107.53 | 0.25% |
| NZX 50 Index | 12,875.80 | 82.18 | -0.63% |
| S&P 500 | 6,465.94 | 26.62 | 0.41% |
| S&P/ASX 200 | 8,949.00 | 12.20 | -0.14% |
| SSE Composite Index | 3,881.07 | 12.69 | 0.33% |